|  | | | | |
High Risk Heart Failure: | | | | | |
Safety and Efficacy (oral) |  | | | | Phase IIb planning is underway (1) |
Safety and Efficacy (iv) | | | | | Phase IIb planning is underway (1) |
Stable Heart Failure: | | | | | |
Pharmacokinetic (MR/IR - oral) |  | | | | Phase IIa planning underway (1) |
Safety and Tolerability (iv) |  | | | | Phase II completed in Q1 09 |
Ischemic Cardiomyopathy (iv/oral) | | | | | Phase II completed in 2008 |
Healthy Volunteers: | | | | | |
Drug/Drug Interaction (oral) |  | | | | Phase I completed in 2008 |
Single-Dose to Multi-Dose (oral) | | | | | Phase I completed in 2008 |
Oral Modified Release (oral) | | | | | Phase I completed in 2008 |
Safety and Tolerability (iv) | | | | | Phase I completed in 2006 |
Renal Dysfunction: | | | | | |
Pharmacokinetic (MR - oral) |  | | | | Phase I planning is underway (1) |
